Filing Shows Regeneron Stopped Paying CEO and CSO's Club Membership Fees

Biotechnology-drugs maker Regeneron Pharmaceuticals Inc., which has a $50 billion market valuation, said it's cutting some benefits for top executives. Chief Executive Officer Leonard Schleifer and Chief Scientific Officer George Yancopoulos will no longer have credit card fees and automobile allowances paid by the firm, Tarrytown, New York-based Regeneron said in a proxy filing.

http://ift.tt/1OqIvC5